Recordati SpA
REC
Company Profile
Business description
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients.
Contact
Via Matteo Civitali 1
MIlan20148
ITAT: +39 2487871
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
4,580
Stocks News & Analysis
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,105.50 | 5.60 | -0.06% |
| CAC 40 | 7,635.03 | 13.99 | 0.18% |
| DAX 40 | 23,924.36 | 78.29 | 0.33% |
| Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
| FTSE 100 | 9,164.31 | 21.58 | 0.24% |
| HKSE | 24,910.63 | 8.10 | 0.03% |
| NASDAQ | 21,169.42 | 252.87 | 1.21% |
| Nikkei 225 | 41,020.58 | 225.72 | 0.55% |
| NZX 50 Index | 12,879.50 | 0.66 | -0.01% |
| S&P 500 | 6,345.06 | 45.87 | 0.73% |
| S&P/ASX 200 | 8,837.40 | 6.30 | -0.07% |
| SSE Composite Index | 3,633.99 | 16.40 | 0.45% |